Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Neoplasm Metastasis 1

Interventions

Eating 5Standard of Care 4Radiofrequency Ablation 4Exercise 4Surgical Procedures, Operative 3Radiosurgery 3Endoscopic Mucosal Resection 3Adrenalectomy 3lutetium Lu 177 dotatate 2Yoga 2Saline Solution 2Robotic Surgical Procedures 2Resistance Training 2Proton Therapy 2Propofol 2Palliative Care 2Octreotide 2Magnetic Resonance Imaging 2Lutetium-177 2Liquid Biopsy 2Interviews as Topic 2Hydrocortisone 2Diet, Mediterranean 2Diet 2Desflurane 2Data Collection 2Conversion to Open Surgery 2Control Groups 2Calcium 23-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × dabrafenib × Endocrine × Clear all
NCT01534897 2017-03-15

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Massachusetts General Hospital

Phase NA Completed
10 enrolled 9 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡